Tobevibart

Vir Biotechnology will present 24-week subgroup analysis data from its Phase 2 SOLSTICE trial in chronic hepatitis delta at the EASL Congress 2025 in Amsterdam, examining how baseline viral parameters and cirrhosis status affect treatment responses.

Over 50 pharmaceutical companies are actively developing 55+ pipeline therapies for chronic hepatitis B virus (HBV) infection, signaling a robust research landscape aimed at achieving functional cures beyond current suppressive treatments.

New data from Brii Bio's Phase 2 ENSURE study reveals that patients who responded to BRII-179 achieved a 55.6% HBsAg seroclearance rate, compared to just 10% in non-responders, supporting a novel patient enrichment strategy.

Virion Therapeutics' Phase 1b trial of VRON-0200 has completed enrollment for the first two cohorts, involving 27 chronic hepatitis B patients on antiviral therapy.

JPMorgan increased Vir Biotechnology's price target to $14, citing promising early clinical data from its masked Tumor Cell Engagers (TCEs).